Leveraging over 25 years of experience in immune-mediated diseases, Zoë is responsible for leading the scientific direction and strategic planning for the creation of pods new companies. She has guided both small and large molecule drug discovery programs from preclinical research and into clinical development in diseases including oncology, autoimmunity, and inflammation. Zoë earned her Ph.D. in pharmacology from King's College London and received her honours degree in Biological Sciences from the University of Manchester. In her prior positions, she has exhibited exceptional leadership skills, overseeing high-performing teams at prominent pharmaceutical companies such as UCB and Merck, as well as within start-up to mid-sized biotech companies including Novimmune, iOnctura, and Affivant.